A5018625601- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Global Cancer Incidence and Screening
- Cancer Genomics and Diagnostics
- Inflammatory mediators and NSAID effects
- BRCA gene mutations in cancer
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Ethics in Clinical Research
- Growth Hormone and Insulin-like Growth Factors
- Radiomics and Machine Learning in Medical Imaging
- Bone health and treatments
- Peripheral Artery Disease Management
- Diet, Metabolism, and Disease
- Advanced Biosensing Techniques and Applications
- Mental Health and Psychiatry
- Vascular Procedures and Complications
- Reproductive Physiology in Livestock
- Muscle and Compartmental Disorders
- Molecular Biology Techniques and Applications
- Gastroesophageal reflux and treatments
Breast Cancer Trials
2007-2019
Peter MacCallum Cancer Centre
2018-2019
Prince of Wales Hospital
2019
Victorian Comprehensive Cancer Centre
2019
Louisiana State University Health Sciences Center New Orleans
2018
Dana-Farber Cancer Institute
2016-2018
National Institute of Oncology
2018
Regional Cancer Center
2018
University of Limerick
2017
Guy's Hospital
2007-2017
Initial results from the first International Breast Cancer Intervention Study (IBIS-I) found that tamoxifen reduced risk of invasive estrogen receptor (ER)–positive tumors by 31% in women at increased for breast cancer, but most follow-up this time was during active treatment phase. We report an updated analysis IBIS-I focuses on period after completed, a which little evidence other trials is available. A total 7145 who were aged 35–70 years and cancer randomly assigned to receive either (20...
Abstract Background Patients and clinicians report difficulties with the process of informed consent to clinical trials audiotape audits show that critical information is often omitted or poorly presented. Decision aids (DAs) may assist in improving consent. Aims This study piloted a DA booklet for high priority breast cancer prevention trial, IBIS‐II DCIS, which compares efficacy an aromatase inhibitor (anastrozole) tamoxifen women who have had surgery ductal carcinoma situ (DCIS). Method...
Abstract #13 Background: BIG 1-98 compares letrozole (Let), tamoxifen (Tam) and sequences of Let Tam as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Initial results (published in 2005) demonstrated the superiority over significantly prolonging disease-free survival (DFS) reducing risk relapse distant sites. Following these results, investigators were informed treatment allocation patients randomized to alone, about one third opted receive Let. The...
Abstract #53 Background: The Recurrence Score (RS) has been validated for estimating residual risk of distant recurrence (DR) in ER+ node negative (N-) primary breast cancer patients receiving adjuvant tamoxifen. Aromatase inhibitors (AIs) are widely used treatment disease postmenopausal women. RS not evaluated treated with an AI.
 Method: Tumour blocks were collected retrospectively from the monotherapy arms ATAC trial under TransATAC protocol yielding 1308 hormone receptor...
The aim of this study was to provide information on patients current service use which could inform future decisions planning and resource allocation.Individuals with a diagnosis schizophrenia, who had received in-patient care in the previous five years, were identified from Lothian Case Register. Information obtained 193 subjects. Patients' over six-month period examined. costs incurred provision determined.Patients differed markedly their services. This not found be related mental state....
522 Background: Conflicting data exist regarding the association of side effects related to estrogen manipulation with prognosis. We evaluated outcome patients (pts) according early incidence vasomotor and arthralgia/myalgia symptoms. Methods: In BIG 1-98 trial 8010 postmenopausal pts hormone receptor-positive breast cancer were randomized a 5-year regimen tamoxifen (T), letrozole (L), T followed by L, or reverse. This evaluation included L alone who received at least one dose therapy, had...
509 Background: The 21-gene Oncotype DX Recurrence Score (RS) is widely used for assessment of recurrence risk and prediction chemotherapy benefit in patients with early stage ER-positive breast cancer. Pathologic clinical factors such as tumor size grade, patient age also provide independent prognostic utility might be combined the RS to achieve more power. Methods: All NSABP trial B-14 ATAC study who had specimens successful assay were included. node-negative treated tamoxifen....
Abstract Background: IES is an investigator-led study in 4724 postmenopausal patients with early breast cancer (sponsored by Pfizer Ltd; ISRCTN11883920) that has already demonstrated significant, clinically important benefits from switching adjuvant endocrine therapy after 2-3 years tamoxifen (T) to exemestane (E) (NEJM 2004, Lancet 2007). With longer follow-up the sensitivity of a disease free survival analysis may be reduced increasing number non cancer-related deaths. Analysis (BCFS),...
Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin cyclophosphamide followed by docetaxel standard regimen early cancer. In metastatic cancer the combination gemcitabine taxane shown promising results. This phase II study investigated efficacy safety incorporating into neoadjuvant therapy.Female patients that was clinically T2 (≥3 cm) or T3-4, N0-1, M0 were...
Infusions of the following hormones were made into hepatic vein sheep over periods three hours: pentagastrin (2.1, 5.0 or 9.9 micrograms/kg), pancreozymin (1.0 units/kg), secretin (2.0 insulin (2.1 4.3 units/kg). Intake concentrate food was depressed by at micrograms/kg/3 hr (P < 0.05) and increased units/kg/3 hr-(P Insulin levels in jugular plasma unaffected any gut hormone infusions. The liver is suggested as being involved control intake sheep.
Abstract Background Radiation therapy (RT) after breast conserving surgery (BCS) is the current standard of care for patients with early stage cancer. However, individual absolute recurrence risks and hence benefits RT vary substantially. A study showed significant association between local (LR) risk PAM50-defined intrinsic subtypes Risk Recurrence scores (ROR).1 The objective EXPERT, a co-lead Breast Cancer Trials-Australia & New Zealand (BCT-ANZ), International Group (BIG), to optimize...
Abstract Background: As compared to invasive breast cancer (IBC), HER2 is much more frequently overexpressed in ductal carcinoma situ (DCIS). Unlike IBC, the prognostic significance of overexpression remains be established DCIS and large studies investigate its predictive role are lacking. We investigated relevance protein ERBB2 mRNA expression using material from UK/ANZ trial. Methods: Formalin-fixed paraffin embedded tissues (FFPETs) were collected patients enrolled trial, a randomised 2X2...
Abstract BACKGROUND: The SWOG S0230/POEMS study demonstrated a 70% reduction in ovarian failure (OF) with goserelin coadministration during chemotherapy (CT) for ER-negative early breast cancer (BC; Moore H et al, NEJM 2015). Goserelin use was also associated more pregnancies as well favorable disease free survival (DFS) and overall (OS). Here we report the final analysis after 5 years of follow-up. METHODS: Premenopausal women age &lt;50 stage I-IIIA ER/PR-negative BC to be treated...
Abstract Background: Third generation aromatase inhibitors are the most effective endocrine treatment for hormone receptor positive breast cancer in postmenopausal women. Here, we assess efficacy of anastrozole women who do not have cancer, but at high risk developing disease. Methods: A multi-centre randomised placebo-controlled trial 1mg/day oral vs. matching placebo five years was conducted 3864 increased cancer. The primary endpoint incidence (including ductal carcinoma in-situ (DCIS)...
Abstract Background Adjuvant endocrine therapy beyond 5 years is known to be of benefit some ER+ patients but it unclear which have sufficient residual risk (RR) merit this. We previously shown that 4 immunohistochemical markers (ER, PgR, Ki67, HER-2), both alone and combined into the IHC4 score (Cuzick et al, JCO 2011) are significantly correlated with time recurrence (TTR) in overall follow up a cohort 1125 from monotherapy arms Arimidex, Tamoxifen, Alone or combination (ATAC) trial. now...
Abstract Background: One third of breast cancers are now diagnosed in women aged 70 or over. With its high median age at study entry (64 years) the ATAC (1) represents an opportunity to characterise tumour and treatment characteristics a cohort older with early cancer. It also enables us examine effects co-morbidities on competing causes mortality which could have significant influence adjuvant decisions. Materials Methods: Details trial design, methods outcome been published detail...